Replimune Group (REPL)
(Delayed Data from NSDQ)
$10.91 USD
-0.32 (-2.85%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $10.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 1 - 20 ( 202 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Incrementally Positive on Positive Pre-BLA Meeting with FDA
Provider: Roth Capital Partners, Inc.
Analyst: PALUCH B
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Oncolytic Immunotherapy -Initiating coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Tracking to Commercialization; Initiating at Buy and $17 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
We Think IGNYTE Top-Line Primary Data Support BLA Filing; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
IGNYTE-3 in Q3; Central Review Consistent with Investigator Assessment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
BLA Submission For RP1 Expected in 2H24; F3Q24 Results Reported; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q3 Financials; IGNYTE BLA and Confirmatory Trial for 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 + Libtayo Whiffs on CERPASS Endpoints; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Quality, but Just Missing on Quantity; IGNYTE Supports BLA Filing Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Updated ARTACUS Data; F2Q24 Results; Lowering PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Fiscal Financials; Key Early December Update Planned
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
F1Q24 Financial Results Reported; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R